Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
作者： Nadège Gaborit , Moshit Lindzen , Yosef Yarden
DOI: 10.1080/21645515.2015.1102809
关键词: Angiogenesis 、 Metastasis 、 Epidermal growth factor receptor 、 Receptor tyrosine kinase 、 Cancer 、 Bioinformatics 、 Monoclonal antibody 、 Immunotherapy 、 Medicine 、 ERBB3
摘要: Cancer progression depends on stepwise accumulation of oncogenic mutations and a select group growth factors essential for tumor growth, metastasis angiogenesis. Agents blocking the epidermal factor receptor (EGFR, also called HER1 ERBB1) co-receptor HER2/ERBB2 have been approved over last decade as anti-cancer drugs. Because catalytically defective member family, HER3/ERBB3, plays critical roles in emergence resistance carcinomas to various drugs, current efforts focus antibodies other anti-HER3/ERBB3 agents, which we review herein with an emphasis drug combinations some unique biochemical features HER3/ERBB3.
sci-hub.se 参考文章(169)
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
S.A. Prigent, W.J. Gullick, Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. The EMBO Journal. ,vol. 13, pp. 2831- 2841 ,(1994) , 10.1002/J.1460-2075.1994.TB06577.X
Luigi Fattore, Debora Malpicci, Emanuele Marra, Rosalba Camerlingo, Giuseppe Roscilli, Francesca Belleudi, Antoni Ribas, Rita Mancini, Maria Torrisi, Luigi Aurisicchio, Paolo Ascierto, Gennaro Ciliberto, ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors Journal of Translational Medicine. ,vol. 13, pp. 1- 2 ,(2015) , 10.1186/1479-5876-13-S1-K3
C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, A. Ullrich, Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. The EMBO Journal. ,vol. 14, pp. 4267- 4275 ,(1995) , 10.1002/J.1460-2075.1995.TB00101.X
Luigi Aurisicchio, Emanuele Marra, Giuseppe Roscilli, Rita Mancini, Gennaro Ciliberto, The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget. ,vol. 3, pp. 744- 758 ,(2012) , 10.18632/ONCOTARGET.550
Hisato Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio Okamoto, Kiyoko Shibata, Yume Shinkai, Haruka Sakamoto, Michiko Kitano, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells Oncotarget. ,vol. 5, pp. 11847- 11856 ,(2014) , 10.18632/ONCOTARGET.2663
Gaëlle Thomas, Thierry Chardès, Nadège Gaborit, Caroline Mollevi, Wilhem Leconet, Bruno Robert, Nina Radosevic-Robin, Frédérique Penault-Llorca, Céline Gongora, Pierre-Emmanuel Colombo, Yassamine Lazrek, Rui Bras-Goncalves, Ariel Savina, David Azria, Hervé Bazin, André Pèlegrin, Christel Larbouret, HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. ,vol. 5, pp. 7138- 7148 ,(2014) , 10.18632/ONCOTARGET.2231
R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. J. Ratzkin, M. Sela, Y. Yarden, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. The EMBO Journal. ,vol. 15, pp. 2452- 2467 ,(1996) , 10.1002/J.1460-2075.1996.TB00603.X
Pier Paolo Di Fiore, C. Richter King, Philip G. Kasprzyk, Sun Uk Song, Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies Cancer Research. ,vol. 52, pp. 2771- 2776 ,(1992)
I Lax, W H Burgess, F Bellot, A Ullrich, J Schlessinger, D Givol, Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Molecular and Cellular Biology. ,vol. 8, pp. 1831- 1834 ,(1988) , 10.1128/MCB.8.4.1831